COMPANY PROFILE

Affini-T Therapeutics

Explore full profile

Biotechnology company developing T-cell therapies for patients suffering from cancer

Boston, United StatesFounded 2020Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2022

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Affini-T Therapeutics

Affini-T Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the field of gene editing. The company is focused on developing innovative therapies for cancer treatment, with a particular emphasis on targeting the KRAS G12D gene mutation, a common mutation in many types of cancer.

Read full description

The company's primary clients are healthcare providers and patients suffering from cancer. Affini-T Therapeutics operates in the highly competitive and rapidly evolving biotechnology market, which is driven by advancements in scientific research and technology.

The business model of Affini-T Therapeutics is based on research and development (R&D). The company invests heavily in R&D to develop new gene editing therapies. Once these therapies are developed and approved for use, the company generates revenue by selling these therapies to healthcare providers.

The company recently appointed Kathy Bergsteinsson, a veteran in healthcare capital markets, as its Chief Financial Officer, and Thaminda Ramanayake, an industry veteran, as its Chief Business Officer. These appointments suggest that the company is gearing up for significant business growth and expansion.

Affini-T Therapeutics also actively participates in scientific conferences, such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting, to present its preclinical gene editing data. This not only helps the company to stay updated with the latest developments in the field but also provides opportunities to network with other industry players and potential clients.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Boston, United States
Employees: 11
Open positions: None listed
Dealroom signal: 61.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Genetics and genomics, Synthetic Biology, Crispr, Spinout, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Mar 2022	$175M	$700M	Alexandria Venture Investments · Parker Institute for Cancer Immunotherapy · Catalio Capital Management · Erasca Ventures	↗
SPINOUTOther financing	Jan 2020	$0	—	Memorial Sloan - Kettering Cancer Center · Fred Hutchinson Cancer Research Center	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Affini-T Therapeutics website traffic

Latest recorded traffic for Affini-T Therapeutics is 3.8K monthly website visits, up 90% over the last three months. Affini-T Therapeutics's team declined 45% over the past year.

Latest monthly visits3.8K 3-month web change+90% 1-year team growth-45%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EGEGenesisA gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues, and cells to address the global organ crisis	Cambridge, United States	Operational	154	$470M	$764M
ITIntellia TherapeuticsA leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases	Cambridge, United States	Operational
MEMEDICStreamlined cancer drug target discovery/validation by CRISPR functional genomics in cancer organoid models at scale	Mountain View, United States	Operational
GBGraphite BioA next-generation gene editing company focused on fixing genes through targeted DNA integration to cure serious diseases	San Francisco, United States	Acquired
EBEligo BioscienceEligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing	Paris, France	Operational
VTVerve TherapeuticsFocused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary	Cambridge, United States	Acquired
SBSNIPR BiomeSNIPR Biome is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future	Copenhagen, Denmark	Operational
KYKytopenDeveloping an automated cell engineering platform to accelerate discovery of bioengineered chemicals	Cambridge, United States	Operational